Percutaneous microwave ablation of renal cancers under CT guidance: safety and efficacy with a 2-year follow-up

Chan, Paul S.; Velasco, Stéphane; Vesselle, G.; Boucebci, S.; Herpe, Guillaume; Debaene, B.; Ingrand, Pierre; Irani, Jacques; Tasu, J.P.

doi:10.1016/j.crad.2017.03.029

Cited by 34 publications

(22 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After repeated MWA(s), a secondary efficacy of 99% was reached for T1a tumours. In the literature, primary efficacy rates of MWA from 84.6 to 100% are reported [8,11,14,22,29]. Therefore, the primary and secondary efficacy of T1a tumours underpins the existing evidence supporting MWA for the treatment of T1a RCC lesions.…”

Section: Discussionmentioning

confidence: 99%

Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell Carcinoma

Aarts

Prevoo

Meier

et al. 2020

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Objectives To assess the safety and efficacy of percutaneous microwave ablation (MWA) of histologically proven T1 renal cell carcinoma (RCC). Methods We analysed patients with a histologically proven RCC (B 7 cm) treated by MWA from April 2012-April 2018. Primary and secondary efficacy, local tumour recurrence (LTR), morbidity and mortality were reported. Efficacy was defined as no residual tumour enhancement on follow-up imaging 1 month after the first ablation (primary efficacy) and after re-ablation(s) for residual disease (secondary efficacy). Adverse events (AE) were registered by the Clavien-Dindo classification and the common terminology criteria for AE. Univariable and multivariable logistic regression analyses were performed to investigate a relation among pre-treatment factors incomplete ablation and complications. Results In 100 patients, a total of 108 RCCs (85 T1a and 23 T1b) were treated by MWA. Median size was 3.2 cm (IQR 2.4-4.0). Primary efficacy was 89% (95%CI 0.81-0.94) for T1a lesions and 52% (95%CI 0.31-0.73) for T1b lesions (p \ 0.001). Fifteen lesions (7 T1a) were reablated for residual disease by MWA in one (n = 13) and two (n = 2, both T1b) sessions resulting in secondary efficacy rates of 99% (T1a) and 95% (T1b, p = 0.352). LTR occurred in four tumours (2 T1a, 2 T1b) after 10-60 months. Six (4%) AEs grade [ 3-5 were observed (2 T1a, 4 T1b, p = 0.045). Multivariable analysis showed that mR.E.N.A.L. nephrometry was independently associated with incomplete ablation (p = 0.012). Conclusion Microwave ablation is safe and effective for T1a and T1b RCC lesions with a significantly lower primary efficacy for T1b lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell Carcinoma

Aarts

Prevoo

Meier

et al. 2020

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

show abstract

“…Nine studies, including 552 lesions treated with MWA, were included (►Table 2). [54][55][56][57][58][59][60][61][62] All but one study pertained to percutaneous approach alone. Average lesion size was 2.8 cm.…”

Section: Review Of Contemporary Oncologic Outcomesmentioning

confidence: 99%

Systematic Review of Contemporary Evidence for the Management of T1 Renal Cell Carcinoma: What IRs Need to Know for Kidney Cancer Tumor Boards

Cronan

Dariushnia

Bercu

et al. 2019

Semin intervent Radiol

View full text Add to dashboard Cite

Renal cell carcinoma is a relatively common malignancy, with 60 to 70 thousand cases a year in the United States alone. Increased utilization of cross-sectional imaging has led to an increase in the number of early renal cell cancers seen by the medical establishment. In addition, certain patient populations have an increased risk of developing kidney cancers which may mandate aggressive screening protocols. This article discusses the epidemiology of renal cell cancers; discusses the current management guidelines from multiple specialty societies; discusses some of the surgical and interventional techniques used in the treatment of such lesions; and provides a review of the literature regarding treatments of early-stage renal cell cancers.

show abstract

“…Microwave ablation is a heat-based modality with a mechanism of cell death identical to that of other thermal ablation techniques, but which offers several physical advantages associated with the delivery of heat ( 5 6 ). As MWA has several advantages over RFA, including higher intratumoral temperatures, larger ablation volumes, and quicker ablation ( 7 ), multiple studies have recently investigated and reported the efficacy and safety of MWA ( 4 8 9 10 11 12 13 14 15 16 17 18 19 ). However, the results were varied, and most of the studies included a small number of patients, with limited precision of the estimated efficacy and safety of MWA.…”

Section: Introductionmentioning

confidence: 99%

“…This meta-analysis included studies which were published between 2010 and 2012. However, 13 percutaneous MWA studies were published after this meta-analysis (since 2012) ( 4 8 9 10 11 12 15 16 17 18 19 ). Hence, we believe that it is timely and important to establish a systematic summary regarding the efficacy and safety of MWA for the management of malignant renal tumor.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Microwave Ablation for Malignant Renal Tumors: An Updated Systematic Review and Meta-Analysis of the Literature Since 2012

Choi

Kim

et al. 2018

Korean J Radiol

View full text Add to dashboard Cite

ObjectiveTo systematically determine the treatment outcomes of percutaneous microwave ablation (MWA) in patients with malignant renal tumor.Materials and MethodsOriginal studies that reported the clinical outcomes of MWA in patients with malignant renal tumors were identified in MEDLINE and EMBASE from 2012 to June 30, 2017. Inverse variance and random-effects models were used to evaluate and acquire meta-analytic summary estimates of various clinical outcomes, including technical outcomes (technical success rate [TSR] and technical efficacy rate [TER]), oncologic outcomes (local tumor recurrence rate [LRR], cancer-specific survival rate [CSSR], and overall survival rate [OSR]), and complications.ResultsAmong the 145 articles screened, 13 articles including 567 patients carrying 616 malignant renal tumors were included in the meta-analysis. The meta-analytic pooled TSR and TER were 97.3% (95% confidence interval, 94.3–99.4%; I2 = 0.0%) and 97.6% (95.0–99.4%, I2 = 48.5%), respectively. The meta-analytic pooled LRR was 2.1% (0.3–4.7%, I2 = 54.1%). At 1-, 2-, 3-, and 5-year follow-up time points, the meta-analytic pooled CSSRs were 99.1% (97.2–100.0%; I2 = 0.0%), 98.4% (95.1–100.0%; I2 = 31.2%), 97.6% (93.4–99.9%; I2 = 52.3%), and 96.9% (93.3–99.2%; I2 = 0.0%) respectively, while the OSRs were 98.3% (96.1–99.8%; I2 = 0.0%), 94.9% (91.7–97.5%; I2 = 0.0%), 86.8% (81.9–91.1%; I2 = 22.1%), and 81.9% (75.4–87.6%; I2 = 0.0%). In terms of major complications, a 1.8% (0.6–3.3%; I2 = 0.0%) rate of meta-analytic pooled incidence was found.ConclusionMicrowave ablation showed favorable technical and oncologic outcomes with a low incidence of major complications. Hence, image-guided percutaneous MWA can be considered as a safe and effective treatment for malignant renal tumors.

show abstract

Percutaneous microwave ablation of renal cancers under CT guidance: safety and efficacy with a 2-year follow-up

Cited by 34 publications

References 24 publications

Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell Carcinoma

Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell Carcinoma

Systematic Review of Contemporary Evidence for the Management of T1 Renal Cell Carcinoma: What IRs Need to Know for Kidney Cancer Tumor Boards

Efficacy and Safety of Microwave Ablation for Malignant Renal Tumors: An Updated Systematic Review and Meta-Analysis of the Literature Since 2012

Contact Info

Product

Resources

About